Fingerprint
Dive into the research topics of 'Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors
Howard A. Burris, Jeffrey R. Infante, Stephen M. Ansell, John J. Nemunaitis, Geoffrey R. Weiss, Victor M. Villalobos, Branimir I. Sikic, Matthew H. Taylor, Donald W. Northfelt, William E. Carson, Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, Tibor Keler, Timothy Bullock
Research output: Contribution to journal › Article › peer-review
102
Scopus
citations